Acutus Medical AI Stock Analysis
Want to see AFIB full AI Analyst Report?
Acutus Medical (AFIB) AI Stock Analysis
Acutus Medical
(Other OTC:AFIB)
Acutus Medical's overall stock score is primarily impacted by its poor financial performance and valuation metrics. The company is unprofitable with negative cash flows and a highly leveraged balance sheet, posing significant investment risks. Technical analysis also indicates bearish momentum, further weighing on the stock's prospects.
Acutus Medical (AFIB) vs. SPDR S&P 500 ETF (SPY)
Not enough price history over this period.
- Market Cap
- $2,991
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- 0.0
- Beta (1Y)
- 5.02
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 85
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Acutus Medical Business Overview & Revenue Model
Company Description
Acutus Medical, Inc. is a company dedicated to the treatment of cardiac arrhythmias, focusing on the design, manufacturing, and commercialization of specialized tools for catheter-based ablation procedures. These solutions are utilized to manage a sp...
How the Company Makes Money
Acutus Medical generates revenue primarily through the sale of its medical devices and systems used in electrophysiology procedures. The company’s revenue model includes direct sales of its AcQMap® systems and disposable catheters to hospitals and cl...
Acutus Medical Financial Statement Overview
Summary
Acutus Medical faces significant financial challenges with unprofitable operations, negative margins, and a highly leveraged balance sheet. The company is struggling to maintain financial stability, as indicated by the negative cash flows and insolvency risk highlighted in the financial statements.
Income Statement
45NeutralBalance Sheet
30NegativeCash Flow
40Negative| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 20.16M | 20.16M | 7.16M | 3.03M | 17.26M | 8.46M |
| Gross Profit | 1.00M | 1.01M | -3.14M | -1.91M | -15.66M | -7.42M |
| EBITDA | 2.25M | 2.25M | -5.33M | 35.20M | -105.12M | -92.55M |
| Net Income | -9.55M | -9.55M | -81.66M | -39.62M | -117.68M | -101.98M |
Balance Sheet | ||||||
| Total Assets | 28.65M | 28.65M | 53.96M | 133.44M | 169.79M | 192.53M |
| Cash, Cash Equivalents and Short-Term Investments | 14.02M | 14.02M | 22.40M | 70.45M | 100.77M | 131.07M |
| Total Debt | 35.76M | 35.76M | 38.48M | 38.86M | 45.40M | 41.08M |
| Total Liabilities | 40.24M | 40.24M | 54.84M | 58.42M | 64.07M | 65.95M |
| Stockholders Equity | -11.59M | -11.59M | -879.00K | 75.02M | 105.73M | 126.58M |
Cash Flow | ||||||
| Free Cash Flow | -31.77M | -31.77M | -63.34M | -89.02M | -109.66M | -96.39M |
| Operating Cash Flow | -31.66M | -31.66M | -63.12M | -85.03M | -99.68M | -85.17M |
| Investing Cash Flow | 22.15M | 22.15M | 58.55M | 104.75M | 19.07M | -63.82M |
| Financing Cash Flow | -2.89M | -2.89M | -2.66M | -12.12M | 79.57M | 164.43M |
Acutus Medical Risk Analysis
Acutus Medical disclosed 63 risk factors in its most recent earnings report. Acutus Medical reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksAcutus Medical Peers Comparison
Overall Rating
RCEL60Neutral
COCH53Neutral
CLPT43Neutral
ECOR42Neutral
AFIB39Underperform
PAVM26Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 60Neutral | $502.41M | -13.44 | 146.38% | ― | 16.96% | 34.83% | |
| 53Neutral | $51.89M | -1.80 | -9999.00% | ― | 11.06% | 64.70% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 43Neutral | $234.32M | -6.04 | -170.24% | ― | 32.51% | -46.56% | |
| 42Neutral | $44.75M | -3.39 | 498.83% | ― | 27.26% | 20.47% | |
| 39Underperform | $2,991 | 0.00 | 153.11% | ― | ― | ― | |
| 26Underperform | $9.60M | -0.13 | -58.07% | ― | 410.34% | -185.92% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AFIB | Acutus Medical, Inc. | ― | ― | ― | |
| RCEL | Avita Medical Ltd | 15.99 | 12.20 | 321.90% | |
| CLPT | Clearpoint Neuro, Inc. | 7.31 | -6.51 | -47.11% | |
| ECOR | Electrocore | 4.85 | 0.14 | 2.97% | |
| PAVM | Pavmed | 1.20 | -8.92 | -88.14% | |
| COCH | Envoy Medical, Inc. Class A | 6.70 | -0.51 | -7.10% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: May 22, 2025
